Filaggrin mutations up risk of irritant contact dermatitis

October 14, 2012
Filaggrin mutations up risk of irritant contact dermatitis
Both atopic dermatitis and loss-of-function mutations in the filaggrin gene are independently associated with an increased risk of developing chronic irritant contact dermatitis, with people having both mutations at about a five-fold higher risk, according to research published online Oct. 5 in the British Journal of Dermatology.

(HealthDay)—Both atopic dermatitis (AD) and loss-of-function mutations in the filaggrin gene (FLG) are independently associated with an increased risk of developing chronic irritant contact dermatitis (ICD), with people having both mutations at about a five-fold higher risk, according to research published online Oct. 5 in the British Journal of Dermatology.

Noting that loss-of-function mutations in FLG increase the risk for AD, Maaike J. Visser, M.D., of the Coronel Institute for Occupational Health in Amsterdam, and colleagues conducted a study involving 634 subjects with chronic ICD and 393 controls to investigate the relative contribution and interaction of FLG mutations and AD in ICD.

The researchers found that 15.9 percent of ICD patients and 8.3 percent of control patients had an FLG mutation, with a crude odds ratio of 2.09 for the combined carrier allele. After correcting for AD, the adjusted odds ratio for FLG mutations was 1.62, and individuals with AD had an odds ratio of 2.89 for developing ICD. Concomitant presence of both AD and FLG mutations resulted in a 4.7-fold increased risk of ICD.

"In summary, our results indicate that both FLG loss-of-function mutations and AD significantly increase the risk for ICD, with respective odds ratios of 1.61 and 2.89," the authors write. "Individuals with both FLG and AD have an approximately four- to five-fold increased risk to develop ICD."

Explore further: ICD-9 codes underestimate statin-linked rhabdomyolysis

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

ICD-9 codes underestimate statin-linked rhabdomyolysis

April 18, 2012

(HealthDay) -- Use of diagnostic codes, such as International Classification of Diseases -- Ninth Revision (ICD-9) codes, may result in misclassification of rare, adverse drug reactions (ADRs), including the risk of rhabdomyolysis ...

Heart medication converts cancer cells into vaccine

July 23, 2012

(HealthDay) -- A class of heart medications, cardiac glycosides, can induce immunogenic cell death (ICD), whereby dying cancer cells are converted into a vaccine that stimulates antitumor response, according to a study published ...

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.